China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

Nicole DeFeudis

Editor

Nearly a year after Nanjing, China-based InxMed bagged its first-ever IND approval, the company has raked in ¥130 million (about $19 million) in a Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

Nicole DeFeudis

Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Chi­na biotech In­xMed bags $19M Se­ries A+ to de­vel­op PhI FAK in­hibitor

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam